NCT00000338Unknown1 期
Infusion Laboratory: Protocol 2 (Lisuride)
适应症
相关药物
试验速览
- 阶段
- 1 期
- 入组人数
- 2
- 试验地点
- 2
- 主要终点
- Evidence of change in neurophysiology and brain ac
研究概览
简要总结
The purpose of this study is to evaluate clinical safety issues pertaining to lisuride, to cocaine, and to its interaction in a chronic, crack dependent population, and to determine how pretreatment with lisuride modifies the subjective as well as physiological effects of cocaine.
研究设计
- 研究类型
- Interventional
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 21 Years 至 50 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •M/F ages 21-
- •Meet DSM-IV criteria for cocaine dependence. Agree to conditions of the study and sign informed consent.
排除标准
- •Psychiatric disorder that requires medication therapy. History of seizures. Pregnant and/or nuring women. Dependence on ETOH or benzodiazepines or other sedative/hypnotics. Acute hepatitis. Other medical condtions that deem participation to be unsafe.
结局指标
主要结局
Evidence of change in neurophysiology and brain ac
Clinical physiological response to cocaine challen
Characterization of study population
Degree of drug craving
History, incidence and amount of drug use
Type and severity of stimulant withdrawal symptoms
Evidence of change in subjective responses to coca
Frequency and intensity of drug use and sexual beh
Degree to which study medication influences change
Population incidence of symptoms of depression, po
次要结局
未报告次要终点
研究者
研究点 (2)
Loading locations...
相似试验
Unknown
1 期
Infusion Laboratory: Protocol 3 (Risperidone) - 4Cocaine-Related DisordersNCT00000339National Institute on Drug Abuse (NIDA)13
Unknown
1 期
Infusion Laboratory: Protocol 4 (Dihydrexidine) - 13Cocaine-Related DisordersNCT00000348National Institute on Drug Abuse (NIDA)
已完成
2 期
Evaluate the Safety, Pharmacodynamics, Pharmacokinetics, and Exploratory Efficacy of GZ/SAR402671 in Treatment-naïve Adult Male Patients With Fabry DiseaseFabry DiseaseNCT02228460Genzyme, a Sanofi Company11
Unknown
1 期
Infusion Laboratory: Protocol 5 (Flupenthixol) - 14Cocaine-Related DisordersNCT00000349National Institute on Drug Abuse (NIDA)
已完成
2 期
A Study to Determine the Safety and Tolerability of Dupilumab (REGN668/SAR231893) in Patients Aged ≥6 to <18 Years With Atopic Dermatitis (Eczema)Atopic DermatitisNCT02407756Regeneron Pharmaceuticals78